Stevanato Group to Report Third Quarter Financial Results on November 9
PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the third quarter of fiscal 2021 on Tuesday, November 9, 2021 at 6:30 a.m. Eastern Time (12:30 CET).
The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET) on November 9, 2021. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, please visit the “Financial Results” page, under the Financial Information tab of the Company's Investor Relations section of its website.
To participate on the call please dial:
United States: 855 979 6654
United Kingdom: 0800 640 6441
Canada: 833 294 2546
Italy: 800 684 570
International: +44 20 3936 2999
Access Code: 659819
Listeners are encouraged to preregister for the call via the following link: https://www.incommglobalevents.com/registration/client/8953/stevanato-q3-earnings-call/, whereupon you will be provided with a unique dial-in number and access code.
For Participants that do not preregister:
A live broadcast of the conference call will also be available online at the following link: www.incommuk.com/customers/online (access code 659819).
An online archive of the broadcast will be available at the website shortly after the live call and will be available through Tuesday 23 November 2021. The recording will be accessible via the following link: https://www.incommglobalevents.com/replay/6910/stevanato-q3-earnings-call/ (access code 889042).
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
For more information, please visit www.stevanatogroup.com
Source: Stevanato Group S.p.A.
Released October 27, 2021